Altintas; Isil
Patent Applications and Registrations
Patent applications and USPTO patent grants for Altintas; Isil.The latest application filed is for "multispecific antibodies against cd40 and cd137".
- Altintas; Isil - Utrecht NL
- ALTINTAS; Isil - Copenhagen V DK
| Patent | Date |
|---|---|
| Multispecific antibodies against CD40 and CD137 Grant 11,440,966 - Altintas , et al. September 13, 2 | 2022-09-13 |
| Humanized or chimeric CD3 antibodies Grant 11,359,015 - Rademaker , et al. June 14, 2 | 2022-06-14 |
| Multispecific Antibodies Against Cd40 And Cd137 App 20220064317 - ALTINTAS; Isil ; et al. | 2022-03-03 |
| Multispecific Antibodies Against Cd40 And Cd137 App 20220033510 - ALTINTAS; Isil ; et al. | 2022-02-03 |
| Antibody Formulation App 20210369842 - ALTINTAS; Isil ; et al. | 2021-12-02 |
| Multispecific Antibodies Against Cd40 And Cd137 App 20210317225 - ALTINTAS; Isil ; et al. | 2021-10-14 |
| Binding Agents Binding To Pd-l1 And Cd137 And Use Thereof App 20210277133 - ALTINTAS; Isil ; et al. | 2021-09-09 |
| Binding Agents Binding To Pd-l1 And Cd137 And Use Thereof App 20210269541 - ALTINTAS; Isil ; et al. | 2021-09-02 |
| Agonistic Tnf Receptor Binding Agents App 20210253725 - Sahin; Ugur ; et al. | 2021-08-19 |
| Methods of producing multispecific antibodies against CD40 and CD137 Grant 11,091,557 - Altintas , et al. August 17, 2 | 2021-08-17 |
| Multispecific antibodies against CD40 and CD137 Grant 11,084,882 - Altintas , et al. August 10, 2 | 2021-08-10 |
| Binding Agents Binding To Pd-l1 And Cd137 And Use Thereof App 20210163616 - ALTINTAS; Isil ; et al. | 2021-06-03 |
| Binding agents binding to PD-L1 and CD137 and use thereof Grant 10,968,280 - Altintas , et al. April 6, 2 | 2021-04-06 |
| Agonistic tumor necrosis factor (TNF) receptor binding agents Grant 10,927,181 - Sahin , et al. February 23, 2 | 2021-02-23 |
| Multispecific Antibodies Against Cd40 And Cd137 App 20200247899 - Kind Code | 2020-08-06 |
| Antibodies Against Pd-l1 App 20200239579 - ALTINTAS; Isil ; et al. | 2020-07-30 |
| Humanized Or Chimeric Cd3 Antibodies App 20200199229 - VAN DEN BRINK; Edward Norbert ; et al. | 2020-06-25 |
| Bispecific Antibodies Against Cd3 And Cd20 App 20200199231 - ENGELBERTS; Patrick ; et al. | 2020-06-25 |
| Binding Agents Binding To Pd-l1 And Cd137 And Use Thereof App 20200165349 - ALTINTAS; Isil ; et al. | 2020-05-28 |
| Agonistic Tnf Receptor Binding Agents App 20200079866 - Sahin; Ugur ; et al. | 2020-03-12 |
| Multispecific Antibodies Against Cd40 And Cd137 App 20200062853 - ALTINTAS; Isil ; et al. | 2020-02-27 |
| Bispecific antibodies against CD3 and CD20 Grant 10,544,220 - Engelberts , et al. Ja | 2020-01-28 |
| Methods of inducing T cell activation by administering an antibody comprising CD40 and 4-1BB (CD137) binding domains Grant 10,457,735 - Sahin , et al. October 29, 2 | 2019-10-29 |
| Humanized Or Chimeric Cd3 Antibodies App 20190284278 - RADEMAKER; Rik ; et al. | 2019-09-19 |
| Humanized or chimeric CD3 antibodies Grant 10,407,501 - Van Den Brink , et al. Sept | 2019-09-10 |
| Agonistic Tnf Receptor Binding Agents App 20180194849 - Sahin; Ugur ; et al. | 2018-07-12 |
| Bispecific Antibodies Against Cd3 And Cd20 App 20170355767 - ENGELBERTS; Patrick ; et al. | 2017-12-14 |
| Humanized Or Chimeric Cd3 Antibodies App 20160333095 - VAN DEN BRINK; Edward Norbert ; et al. | 2016-11-17 |
| Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith Grant 9,339,554 - Rijcken , et al. May 17, 2 | 2016-05-17 |
| Tunable, Biodegradable Linker Molecules For Transient Conjugation Of Components In Drug Delivery Systems, And Drug Delivery Systems Prepared Therewith App 20130261094 - Rijcken; Cristianne Johanna Ferdinand ; et al. | 2013-10-03 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 